AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18444850
Drug: Clarithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (1 g, intravenously once daily for 3 consecutive days)
Trial: 14517188
Drug: Unpurged high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpurged high-dose therapy (U)
Trial: 14517188
Drug: Purged high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purged high-dose therapy (P)
Trial: 9094873
Drug: Iron-fortified, cow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified, cow milk-based infant formula (465 mg Ca and 317 mg P/L)
Trial: 9094873
Drug: Iron-fortified infant
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified infant formula with added calcium glycerophosphate (1800 mg Ca and 1390 mg P/L)
Trial: 1098751
Drug: Althesin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Althesin (0.05 ml/kg)
Trial: 30342394
Drug: FLZ tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLZ tablets, administered orally, dosage not specified, duration not specified
Trial: 25960085
Drug: riluzole plus
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: riluzole plus mexiletine 300 mg
Trial: 25960085
Drug: riluzole 100
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: riluzole 100 mg
Trial: 19607949
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (IVV) with 1 million units (Mu) of alpha interferon
Trial: 19607949
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (IVV) with 10 million units (Mu) of alpha interferon
Trial: 19607949
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (IVV) alone
Trial: 17885853
Drug: Intranasal ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal ciclesonide 200 micro g once daily
Trial: 17885853
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate-salmeterol (FP-SAL) 500 to 50 micro g twice daily
Trial: 17885853
Drug: Dexamethasone 2
RxNorm normalized name: dexamethasone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 2 mg single dose
Trial: 15236630
Drug: Roxil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxil (500 mg capsule)
Trial: 15236630
Drug: Ultracef (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultracef (500 mg capsule)
Trial: 12133499
Drug: Transcranial Magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup with early TMS treatment.
Trial: 12133499
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TMS), basic treatment same as TMS group.
Trial: 9822239
Drug: 0.25% fluorometholone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% fluorometholone eyedrops four times daily before and after argon laser trabeculoplasty
Trial: 9822239
Drug: Placebo eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eyedrops four times daily before and after argon laser trabeculoplasty
Trial: 7484996
Drug: Combined bile
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bile acid therapy (chenodeoxycholic acid 500 mg/day and ursodeoxycholic acid 500 mg/day)
Trial: 7484996
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid alone (1000 mg/day)
Trial: 7484996
Drug: Combined bile
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bile acid therapy
Trial: 7443776
Drug: Lithium salts
RxNorm normalized name: LITHIUM SALTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium salts with concomitant antidepressive medication (moderate doses for 4 weeks)
Trial: 31782181
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) - 0.5g/kg on day 1, 1g/kg on day 2, 0.6g/kg on weeks 3 and 5
Trial: 31782181
Drug: Volume-matched intravenous
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volume-matched intravenous normal saline (placebo)
Trial: 26057085
Drug: 6% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydrogen peroxide bleaching agent
Trial: 26057085
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide bleaching agent
Trial: 16390282
Drug: Constructive worry
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constructive worry intervention (recording possible solutions to worries)
Trial: 1793675
Drug: oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral oestradiol valerate in a cyclical combination with cyproterone acetate (n = 19)
Trial: 6422478
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg fenoprofen calcium 3-times daily
Trial: 6422478
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg naproxen sodium 3-times daily
Trial: 24621960
Drug: L-citrulline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline (10 g)
Trial: 24621960
Drug: Placebo (L-alanine)
RxNorm normalized name: L-alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (L-alanine)
Trial: 15763437
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (8 g/day for 6 weeks)
Trial: 10483898
Drug: Ala‐Gln (Dipeptiven,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ala‐Gln (Dipeptiven, 0.50 g/kg per day)
Trial: 8743406
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of naproxen
Trial: 8743406
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of naproxen
Trial: 1686440
Drug: Previous formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous formula (Mg++ salt of N-acetyl-aspartylglutamic acid)
Trial: 6435085
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (Theo-Dur)
Trial: 30136743
Drug: Gesture-Verbal Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gesture-Verbal Treatment (GVT)
Trial: 30413519
Drug: Smartphone-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based problem-solving therapy (PST) and behavioural activation (BA) apps (Kaiketsu-App and Genki-App) plus treatment as usual (TAU)
Trial: 30413519
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control with treatment as usual (TAU) alone
Trial: 26856215
Drug: Normal-low potassium
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-low potassium target (nLP group, 4.0 mmol/L)
Trial: 26856215
Drug: Normal-high potassium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-high potassium target (nHP group, 4.5 mmol/L)
Trial: 25417401
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule (XFC) treatment group
Trial: 21958494
Drug: Meropenem (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (20 mg/kg q12h or q8h depending on age)
Trial: 18431478
Drug: Oral amoxycillin
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amoxycillin (31-54 mg/Kg/day, in three divided doses for three days)
Trial: 16191242
Drug: Memantine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine at a standard daily dose of 10 mg b.i.d.
Trial: 10798610
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) - fish oil extract (EPA 3.2 g, DHA 2.4 g)
Trial: 8689472
Drug: Psychoanalytical group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytical group therapy
Trial: 1686811
Drug: D,L-fenfluramine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L-fenfluramine (60 mg, oral)
Trial: 31668850
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (oral exemestane 25 mg per day for 28 days, oral palbociclib 125 mg per day for 21 days every 4 weeks, plus leuprolide 3·75 mg subcutaneously every 4 weeks)
Trial: 31668850
Drug: Capecitabine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks)
Trial: 17616331
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment (n=24)
Trial: 17616331
Drug: HIV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV treatment only (n=115)
Trial: 15832066
Drug: Self-exposure cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-exposure cognitive behaviour therapy (CBT) via FearFighter (FF)
Trial: 9817161
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of antibodies to IL-3, IL-5 and GM-CSF
Trial: 2693162
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 and 600 mg daily
Trial: 29725853
Drug: Duo (D)
RxNorm normalized name: Effaclar Duo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duo (D) implant
Trial: 29725853
Drug: Integra (IN)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integra (IN) implant
Trial: 29725853
Drug: Standard geometry,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard geometry, Duo (D), Compact (C), Infra (IF) implants
Trial: 21802124
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg daily for ≤30 days)
Trial: 21802124
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg retard daily for ≤30 days)
Trial: 19406908
Drug: Clodronate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 0.5 mg one IA injection/week for 4 weeks
Trial: 19406908
Drug: Clodronate 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1 mg one IA injection/week for 4 weeks
Trial: 19406908
Drug: Clodronate 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 2 mg one IA injection/week for 4 weeks
Trial: 19406908
Drug: Clodronate 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1 mg two IA injections/week for 2 weeks
Trial: 19406908
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) 20 mg one IA injection/week for 4 weeks
Trial: 1357998
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (combined regimens)
Trial: 30110008
Drug: Cold tumescence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold tumescence anesthesia solution (4 ℃)
Trial: 30110008
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature tumescence anesthesia solution (24 ℃)
Trial: 25079064
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (verteporfin PDT and ranibizumab)
Trial: 9267791
Drug: Total Androgen
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Androgen Blockade (TAB) by bilateral orchiectomy and flutamide 250 mg t.i.d.
Trial: 9267791
Drug: Combined Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Total Androgen Blockade plus weekly epirubicin 25 mg/m2 i.v. for 18 weeks (E-TAB)
Trial: 9267791
Drug: Combined Total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Total Androgen Blockade plus weekly epirubicin (E-TAB)
Trial: 7506154
Drug: Nimesulide 100mg
RxNorm normalized name: nimesulide 100 MG
DrugBank: Nimesulide (DB04743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100mg 3 times daily
Trial: 3101530
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (8 patients, 5% dextrose in water solution)
Trial: 31589276
Drug: Free distribution
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free distribution of essential medicines (n = 395)
Trial: 24840109
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days starting on day 5 of menses (Group 1)
Trial: 24840109
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days starting the next day after finishing medroxyprogesterone acetate (MPA) (Group 2)
Trial: 24840109
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (Group 2)
Trial: 22872647
Drug: Entecavir 1.0
RxNorm normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1.0 mg/day
Trial: 12825872
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FS and FOBT
Trial: 10713235
Drug: Modified Ringer's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Ringer's solution
Trial: 1353507
Drug: nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol 5 mg once a day (n = 26)
Trial: 1353507
Drug: nifedipine sustained-release
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine sustained-release 20 mg bid (n = 25)
Trial: 30894212
Drug: Epacadostat (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat (25, 50, 100, or 300 mg BID; 75 mg daily; or 50 mg BID intermittent) plus ipilimumab 3 mg/kg every 3 weeks
Trial: 30894212
Drug: Epacadostat (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat (various doses) plus ipilimumab
Trial: 30894212
Drug: Epacadostat (≥25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat (≥25 mg BID) plus ipilimumab
Trial: 23114185
Drug: Loxostylis alata
RxNorm normalized name: Dioscorea alata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxostylis alata extract at doses of 100 mg/kg and 200 mg/kg
Trial: 23114185
Drug: Ketoconazole at
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole at a dose of 60 mg/kg
Trial: 17065169
Drug: i.v. saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. saline 5 ml (control)
Trial: 11868855
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (dietary control, exercise) and placebo capsules
Trial: 9014542
Drug: Doxapram (0.18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (0.18 mg.kg‐1)
Trial: 9014542
Drug: Pethidine (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (0.35 mg.kg‐1)
Trial: 8198023
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg every PM for 6 weeks followed by 20 mg twice daily for an additional 6 weeks
Trial: 3480840
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 vaginal suppository (2.5 mg PGE2 in Witepsol S55)
Trial: 3480840
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 vaginal suppository
Trial: 27194403
Drug: Intravenous Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Plasma-Lyte 148 at 2 mL·kg(‐1) (low volume)
Trial: 27194403
Drug: Intravenous Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Plasma-Lyte 148 at 20 mL·kg(‐1) (high volume)
Trial: 16896786
Drug: Sustained-release chrono
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release chrono VPA (ChVbid, ChVom, ChVoe)
Trial: 12831522
Drug: Tinidazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (50 mg/kg, as a single dose)
Trial: 12831522
Drug: Chloroquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (10 mg/kg twice daily for 5 days)
Trial: 2127744
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g administered orally 1 hour before exercise)
Trial: 2127744
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered orally 1 hour before exercise)
Trial: 36754
Drug: Phenothiazines for
RxNorm normalized name: 10-(2-diethylaminopropyl)phenothiazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenothiazines for narcotic analgesic‐induced emesis
Trial: 21215445
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg vitamin D(3) administered at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment.
Trial: 21215445
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment.
Trial: 21215445
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg vitamin D(3) in patients with tt genotype of TaqI vitamin D receptor polymorphism.
Trial: 21215445
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in patients with tt genotype of TaqI vitamin D receptor polymorphism.
Trial: 21215445
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg vitamin D(3) at 56 days.
Trial: 18798851
Drug: Basiliximab plus
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab plus steroids, mycophenolate mofetil and early initiation of cyclosporin A (CsA) at 3 mg/kg/d within 24 h post-RT
Trial: 18798851
Drug: Basiliximab plus
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab plus steroids, mycophenolate mofetil and early initiation of cyclosporin A (CsA) at 5 mg/kg/d within 24 h post-RT
Trial: 18798851
Drug: Basiliximab plus
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab plus steroids, mycophenolate mofetil and delayed initiation of cyclosporin A (CsA) at 5 mg/kg/d after 7-10 d
Trial: 17146635
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) using polymyxin E, tobramycin, and amphotericin B in throat and gut throughout ICU treatment combined with cefotaxime for 4 days
Trial: 14975783
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VRET) using a head-mounted display (HMD) (low presence)
Trial: 14975783
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VRET) using a computer automatic virtual environment (CAVE) (high presence)
Trial: 11303585
Drug: Soymilk (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk (400 ml daily for 8 weeks)
Trial: 9207869
Drug: Adjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant concurrent chemoradiotherapy with an anthracenedione (50 Gy in 25 fractions over 5 weeks, boost of 15 Gy to the tumor bed when indicated) and chemotherapy (5-fluorouracil, mitoxantrone, and cyclophosphamide at 21-day intervals for 4 to 6 cycles)